RxDoctor Payments Data

Mark Malicki, MD

Family Medicine · Johnstown, PANPI 1083619209

Payments from drug & device makers

$7,616in general payments, 2019–2025

Across 508 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$940
  • GSK$686
  • Novo Nordisk$570
  • AstraZeneca$370
  • Lilly USA, LLC$360
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,596100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,616 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$50,642
Medicare patients
192
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$218,814
JardianceEmpagliflozin44$58,983
XareltoRivaroxaban29$39,905
TrulicityDulaglutide23$38,548
OzempicSemaglutide41$36,779
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$33,940
Synjardy XrEmpagliflozin/Metformin Hcl29$26,794
GlyxambiEmpagliflozin/Linagliptin17$22,637
RybelsusSemaglutide15$22,424
Jentadueto XrLinagliptin/Metformin Hcl28$21,346
Janumet XrSitagliptin Phos/Metformin Hcl20$17,237
TradjentaLinagliptin21$16,104
MyrbetriqMirabegron32$15,447
Atorvastatin Calcium950$15,016
MounjaroTirzepatide13$12,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,378$218,814297 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Jentadueto Xr, Tradjenta$175$145,864139 claims
Novo NordiskOzempic, Rybelsus$570$59,20356 claims
Lilly USA, LLCTrulicity, Mounjaro$360$51,10836 claims
Johnson & JohnsonXarelto$105$39,90529 claims
GSKTrelegy Ellipta, Breo Ellipta$686$38,82857 claims
MerckJanumet Xr, Januvia$216$26,95734 claims
Astellas Pharma US IncMyrbetriq$113$15,44732 claims
AbbVieSynthroid$940$9,411163 claims
AstraZenecaFarxiga$370$7,73013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →